Q1 EPS Estimate for Bicara Therapeutics Increased by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at HC Wainwright increased their Q1 2026 earnings estimates for shares of Bicara Therapeutics in a report released on Tuesday, March 31st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings per share of ($0.64) for the quarter, up from their prior estimate of ($0.72). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.64) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.56) EPS.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.04.

Several other equities analysts have also commented on the company. Bank of America started coverage on Bicara Therapeutics in a research report on Wednesday, March 25th. They set a “buy” rating and a $35.00 price target on the stock. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Citigroup assumed coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They issued an “outperform” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Friday, January 9th. Finally, UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Eight analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $28.00.

Bicara Therapeutics Stock Performance

BCAX stock opened at $21.47 on Thursday. Bicara Therapeutics has a 1 year low of $7.80 and a 1 year high of $21.50. The firm has a market cap of $1.41 billion, a P/E ratio of -8.49 and a beta of -1.23. The stock has a 50-day simple moving average of $17.36 and a 200-day simple moving average of $16.73.

Insider Activity at Bicara Therapeutics

In other news, CEO Claire Mazumdar sold 1,596 shares of the company’s stock in a transaction dated Friday, March 20th. The shares were sold at an average price of $18.95, for a total value of $30,244.20. Following the sale, the chief executive officer owned 339,392 shares in the company, valued at approximately $6,431,478.40. This represents a 0.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Ivan Hyep sold 9,200 shares of the stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $18.52, for a total transaction of $170,384.00. Following the transaction, the chief financial officer directly owned 145,355 shares in the company, valued at $2,691,974.60. The trade was a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 137,969 shares of company stock worth $2,586,198 over the last three months. 15.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Legal & General Group Plc grew its position in shares of Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock valued at $32,000 after acquiring an additional 1,474 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after purchasing an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Bicara Therapeutics during the fourth quarter valued at $45,000. Finally, Larson Financial Group LLC raised its holdings in shares of Bicara Therapeutics by 1,015.5% during the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period.

Trending Headlines about Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its 2026 quarterly and full‑year EPS forecasts (Q1–Q4 and FY2026) and reiterated a “Buy” rating with a $42 price target — the firm trimmed expected losses for each quarter and the year, signaling improved analyst confidence. Read More.
• Positive Sentiment: Wedbush reaffirmed an “Outperform” rating on BCAX, adding third‑party validation from another biopharma‑focused shop that can boost investor sentiment. Read More.
• Positive Sentiment: Goldman Sachs published bullish commentary indicating expected upside for BCAX, which helps drive demand from institutional and retail investors watching analyst cues. Read More.
• Positive Sentiment: Wells Fargo highlighted strong price‑appreciation potential for Bicara, contributing additional buy‑side momentum. Read More.
• Positive Sentiment: Aggregate Wall Street price targets (per Zacks) imply roughly ~55% upside from current levels — the headline can attract momentum traders and investors seeking high‑growth biotechs. Read More.
• Neutral Sentiment: Recent Q4 2025 results showed a slight beat to loss estimates (EPS better than consensus by $0.04), but the company remains unprofitable with consensus FY2026 EPS still a negative figure — investors are reacting to rate of improvement, not profitability yet. Read More.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.